Cited by 874Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

Open access
Roe, Matthew T., Armstrong, Paul W., Fox, Keith A.A., White, Harvey D., Prabhakaran, Dorairaj, Goodman, Shaun G., Cornel, Jan H., Bhatt, Deepak L. +30 more·2012·New England Journal of Medicine

Abstract

BACKGROUND: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. METHODS: In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel. RESULTS: At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P=0.21). Similar results were observed in the overall population. The prespecified analysis of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P=0.04). Rates of severe and intracranial bleeding were similar in the two groups in all age groups. There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group. CONCLUSIONS: Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1205512

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Patients with elevated triglycerides, atherosclerosis, or diabetes receiving statins are at substantial risk for recurrent, potentially fatal ischemic events.

    “In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”

    From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [5]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [12]12. Andersen PK, Gill RD. Cox's regressample study. Ann Stat 1982;10:1100-20.

Cited by

Sorted by citations

Authors
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., Ardissino, D., Nicolau, J. C., Boden, W. E., Gurbel, P. A., Ruzyllo, W., Dalby, A. J., McGuire, D. K., Leiva-Pons, J. L., Parkhomenko, A., Gottlieb, S., Topacio, G. O., Hamm, C., Pavlides, G., Goudev, A. R., Oto, A., Tseng, C.-D., Merkely, B., Gasparovic, V., Corbalan, R., Cinteză, M., McLendon, R. C., Winters, K. J., Brown, E. B., Lokhnygina, Y., Aylward, P. E., Huber, K., Hochman, J. S., & Ohman, E. M.
Affiliations
  • Duke Medical Center (US)
  • University of Alberta (CA)
  • Duke University (US)
  • St. Michael's Hospital (CA)
  • Brigham and Women's Hospital (US)
  • University of Copenhagen (DK)
  • National Taiwan University (TW)
  • Eli Lilly (United States) (US)
  • Flinders University (AU)
Venue
New England Journal of Medicine
Published
2012-10-04
Volume
367
Issue
14
Pages
1297-1309
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2109577952
Cited by
874
References
18
Citations by year
2026: 16 · 2025: 24 · 2024: 14 · 2023: 31 · 2022: 43 · 2021: 49 · 2020: 58 · 2019: 53 · 2018: 70 · 2017: 92 · 2016: 71 · 2015: 91 · 2014: 114 · 2013: 124 · 2012: 20
FWCI
71.23
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
  • Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
  • Trakya University's Institutional Open Access System (Trakya University) (submittedVersion, other-oa)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
  • ORBi (University of Liège) (submittedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion)
Funders
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • Amylin Pharmaceuticals
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Gilead Sciences
  • Helsinn
  • Boston Scientific Corporation
  • Boston VA Research Institute
  • Regeneron Pharmaceuticals
  • Amarin Corporation
  • Medicines Company
  • Regado Biosciences
  • Eisai
  • Astellas Pharma
  • Servier
  • Genentech
  • Janssen Pharmaceuticals
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Health Sciences › Medicine › Surgery › Coronary Interventions and Diagnostics
Keywords
prasugrel, clopidogrel, acute coronary syndrome, non-ST-elevation myocardial infarction, unstable angina, platelet aggregation inhibition, antiplatelet therapy, bleeding risk, heart failure, cardiovascular mortality, stroke, elderly patients
MeSH terms
Prasugrel Hydrochloride, Clopidogrel, Aged, Angina, Unstable, Aspirin, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review